SuperworthTarsus Pharmaceuticals market cap TARS
Share price times shares outstanding: what the whole company sells for, since 2020.
- Today, Oct 23, 2026
- $3B
- Highest close in our data
- $4B
- Sep 2026
Tarsus Pharmaceuticals is worth $3B at the close on Oct 23, 2026, at $68.20 a share.
That is up 7% over the last year and up 424% over five years.
Its highest close in our data was $4B in Sep 2026.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $3B | $2.5B | $4B | −14% |
| 2025 | $3.5B | $1.6B | $3.5B | +65% |
| 2024 | $2.1B | $649.2M | $2.1B | +214% |
| 2023 | $670.4M | $309.3M | $670.4M | +71% |
| 2022 | $391M | $229.5M | $499M | −16% |
| 2021 | $465.2M | $445.8M | $909.9M | −45% |
| 2020 | $839.8M | $454.8M | $1B | n/a |
Against its peers
Companies in Biotechnology nearest Tarsus Pharmaceuticals' size, closest first, today.
| Company | Market cap |
|---|---|
| TARSTarsus Pharmaceuticals | $3B |
| ADMAAdma Biologics | $2.4B |
| VCELVericel | $2.2B |
| KRYSKrystal Biotech | $9.2B |
| RGENRepligen | $10B |
| MGTXMeiraGTx | $884.6M |
| TECHBIO-TECHNE | $11.4B |
| HALOHalozyme Therapeutics | $14.3B |
| NBIXNeurocrine Biosciences | $14.5B |
| EXELExelixis | $16B |
| INCYIncyte | $23.5B |
| Peer median | $10.7B |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Tarsus Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.